Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease | Zendy

A. Michael Lincoff | Zendy; Stephen J. Nicholls | Zendy; Jeffrey Riesmeyer | Zendy; Philip J. Barter | Zendy; H Bryan Brewer | Zendy; Keith A.A. Fox | Zendy; C. Michael Gibson | Zendy; Christopher B. Granger | Zendy; Venu Me | Zendy; Gilles Montalescot | Zendy; Daniel Rader | Zendy; Alan R. Tall | Zendy; Ellen McErlean | Zendy; Kathy Wolski | Zendy; Giacomo Ruotolo | Zendy; Burkhard Vangerow | Zendy; Govinda J. Weerakkody | Zendy; Shaun G. Goodman | Zendy; Diego Conde | Zendy; Darren K. McGuire | Zendy; José Carlos Nicolau | Zendy; José L. Leiva-Pons | Zendy; Yves Pesant | Zendy; Weimin Li | Zendy; David Kandath | Zendy; Simon Kouz | Zendy; Naeem Tahirkheli | Zendy; Denise Mason | Zendy; Steven E. Nissen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Author(s) -

A. Michael Lincoff,

Stephen J. Nicholls,

Jeffrey Riesmeyer,

Philip J. Barter,

H Bryan Brewer,

Keith A.A. Fox,

C. Michael Gibson,

Christopher B. Granger,

Venu Me,

Gilles Montalescot,

Daniel Rader,

Alan R. Tall,

Ellen McErlean,

Kathy Wolski,

Giacomo Ruotolo,

Burkhard Vangerow,

Govinda J. Weerakkody,

Shaun G. Goodman,

Diego Conde,

Darren K. McGuire,

José Carlos Nicolau,

José L. Leiva-Pons,

Yves Pesant,

Weimin Li,

David Kandath,

Simon Kouz,

Naeem Tahirkheli,

Denise Mason,

Steven E. Nissen

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1609581

Subject(s) - medicine , coronary artery disease , placebo , clinical endpoint , stroke (engine) , myocardial infarction , diabetes mellitus , adverse effect , cardiology , randomized controlled trial , endocrinology , pathology , mechanical engineering , alternative medicine , engineering

The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research